Convatec announces Karim Bitar has passed away
London, UK, 27 October 2025: The Board of Directors of Convatec is very sorry to announce that Convatec's CEO, Karim Bitar, who has been on medical leave of absence since 4 August 2025, has sadly passed away.
Colleagues at Convatec are deeply saddened by this devastating news. Our sincerest sympathies are with Karim's wife and family, and we extend our condolences to them.
Dr John McAdam CBE, Chair of the Board of Directors, said: “It has been a tremendous privilege to have worked with Karim for the past six years as he has led the successful transformation of Convatec. Karim was a much admired and respected leader, with strong values, conviction, and above all else, an unshakeable focus on people relying on Convatec products, services and solutions. His impact and legacy at Convatec will be felt for many years and he will be sorely missed by everyone who worked with him.”
As previously announced, interim leadership arrangements remain in place and a further announcement will be made in due course.
Media: MediaRelations@convatec.com
Investor Relations: IR@convatec.com
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com
Press Release
27-Oct-25
Corporate
Convatec announces Karim Bitar has passed away
Interim leadership arrangements remain in place and a further announcement will be made in due course
Read more Read more27-Oct-25
Corporate
Ostomy Care
Stigma, not condition, is the biggest barrier for 1 in 3 people living with c...
New report reveals that millions of people feel they need to hide their health conditions
Read more Read more08-Oct-25
Corporate
Convatec announces closing of $500 Million 5.300% Senior Notes due 2035
Read more Read more02-Oct-25
Corporate
Convatec announces pricing of $500 Million 5.300% Senior Notes due 2035
Read more Read more01-Oct-25
Corporate
Convatec announces plans to invest more than $1 billion in R&D facilities – ...
Major expansions in the US and UK
Read more Read more22-Sep-25
Corporate
Advanced Wound Care
Convatec secures regulatory approval for ConvaMatrix™ in UK and Europe, suppo...
ConvaMatrix has significant potential for the management of hard to heal wounds such as venous leg ulcers and diabeti...
Read more Read more02-Sep-25
Corporate
Advanced Wound Care
Convatec strengthens Leadership Team to support growth
Read more Read more20-Aug-25
Corporate
Convatec commences share buyback programme
Non-discretionary share buyback programme to return up to $300 million of surplus capital to shareholders
Read more Read more29-Jul-25
Corporate
Financial Performance
Interim results for the six months ended 30 June 2025
Delivering broad-based revenue growth, margin expansion & double-digit EPS growth
Read more Read more24-Jul-25
Corporate
Advanced Wound Care
Convatec secures US and European regulatory clearance for Aquacel™ ConvaFiber...
Read more Read more15-Jul-25
Corporate
Advanced Wound Care
Convatec responds to CMS draft payment proposal for skin substitutes in the U...
Convatec notes the draft payment proposal from the Centers for Medicare & Medicaid Services
Read more Read more01-Jul-25
Corporate
Continence Care
Ostomy Care
Comment on CMS proposed rule change issued 30 June 2025
Convatec notes the Centers for Medicare & Medicaid Services (CMS) proposed rule published on 30 June 2025
Read more Read more